Roman Butler Fullerton & Co. Has $692,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Roman Butler Fullerton & Co. has reduced its stake in Bristol Myers Squibb by 29.2%, now holding 14,279 shares valued at $692,000.
• Recent insider trading saw EVP David V. Elkins selling 56,000 shares at an average price of $47.33, decreasing his holdings by 25.07%.
• Bristol Myers Squibb announced a quarterly dividend of $0.62 per share, representing a 5.6% yield, with a total annual payout ratio of 100%.

Roman Butler Fullerton & Co. lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 29.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,279 shares of the biopharmaceutical company's stock after selling 5,899 shares during the period. Roman Butler Fullerton & Co.'s holdings in Bristol Myers Squibb were worth $692,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Beacon Investment Advisory Services Inc. boosted its position in Bristol Myers Squibb by 2.7% during the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock valued at $492,000 after purchasing an additional 212 shares during the last quarter. Exchange Capital Management Inc. raised its stake in shares of Bristol Myers Squibb by 0.4% during the 2nd quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company's stock worth $2,541,000 after purchasing an additional 220 shares in the last quarter. Parsons Capital Management Inc. RI lifted its holdings in shares of Bristol Myers Squibb by 0.3% during the 2nd quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company's stock valued at $3,615,000 after buying an additional 224 shares during the last quarter. Richwood Investment Advisors LLC lifted its holdings in shares of Bristol Myers Squibb by 1.7% during the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company's stock valued at $616,000 after buying an additional 225 shares during the last quarter. Finally, Lipe & Dalton grew its stake in shares of Bristol Myers Squibb by 0.4% in the 1st quarter. Lipe & Dalton now owns 56,999 shares of the biopharmaceutical company's stock valued at $3,476,000 after buying an additional 230 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $44.36 on Thursday. The firm has a market capitalization of $90.29 billion, a PE ratio of 17.89, a PEG ratio of 2.32 and a beta of 0.33. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm's fifty day simple moving average is $45.92 and its 200 day simple moving average is $47.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter in the previous year, the business earned $2.07 EPS. The business's revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.6%. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Analysts Set New Price Targets

BMY has been the subject of a number of analyst reports. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a "moderate buy" rating in a report on Thursday, October 2nd. Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $57.23.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.